EW
stock Healthcare Medical DevicesOverall Mixed · 51%
- Fundamentals Strong
- Trajectory Steady
- Leadership Churning
A read across fundamentals, recent price & growth trajectory, and leadership stability. For fun and reading at a glance, not investment advice.
What the indicators say
Bullish 5 of 5 trend signals bullishRSI 57 — firm momentum, not yet overbought.
A mechanical reading of the chart’s indicators — not investment advice.
Key statsas of Jun 3
- Open
- $86.01
- -1.88%
- Close
- $86.01
- -1.88%
- Current
- $86.01
- Prev close
- $87.66
- Today
- 4.14M
- 3-mo avg
- 5.10M
Earningscalendar synced from Yahoo 57d ago
- Most recent
- Apr 2389 days ago
- Next expected
- Jul 23in 2 days
Recent earnings dates
- Apr 23 89 days ago
- Feb 10 161 days ago
- Oct 30, 2025 264 days ago
- Jul 24, 2025 362 days ago
Past earnings dates come from EW’s 8-K item 2.02 filings; the next date is Yahoo’s when available, otherwise estimated from the recent reporting cadence.
Fundamentalssynced from SEC 51d ago
Across the nine graded ratios (FY2025 balance-sheet figures, P/E on TTM through Mar 2026 earnings, against the latest price), EW’s fundamentals read as strong overall.
At 45.7x, the price is steep relative to profit; the stock leans heavily on growth that has yet to arrive.
Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.
This company pays no dividend, common for firms reinvesting their profits back into growth.
The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.
A 17.7% margin is strong; the company keeps a healthy slice of every revenue dollar.
The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.
A 10.4% return on equity is respectable, in the normal range.
Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.
A 7.8% return on assets is reasonable for a company of this kind.
Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.
At 0.32, the company carries less in liabilities than in equity, a conservative balance sheet.
Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.
At 3.72, short-term assets comfortably cover short-term bills.
Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.
Revenue grew 11.5% from the prior year: strong top-line expansion.
Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.
Net income fell 74.3% from the prior year; profit is shrinking.
Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.
Financialssynced from SEC 51d ago
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Revenue | $5.2B | $4.5B | $5.0B | $5.4B | $6.1B |
| Net income | $1.5B | $1.5B | $1.4B | $4.2B | $1.1B |
| Diluted EPS | $2.38 | $2.44 | $2.30 | $6.97 | $1.83 |
| Dividend / share | — | — | — | — | — |
| Total assets | $8.5B | $8.3B | $9.4B | $13.1B | $13.7B |
| Total liabilities | $2.7B | $2.5B | $2.6B | $3.0B | $3.4B |
| Shareholder equity | $5.8B | $5.8B | $6.7B | $10.0B | $10.3B |
| Q2-2024 | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.4B | $1.4B | $1.4B | $1.5B | $1.6B | $1.6B | $1.6B |
| Net income | $366.3M | $3.1B | $385.6M | $358.0M | $333.2M | $291.1M | $91.2M | $380.7M |
| Diluted EPS | $0.61 | $5.13 | $0.65 | $0.61 | $0.56 | $0.50 | $0.16 | $0.66 |
| Dividend / share | — | — | — | — | — | — | — | — |
Leadershipsynced from SEC 57d ago
- Zovighian Bernard J CEO · Director
- Ullem Scott B. CVP, Chief Financial Officer
- Bobo Donald E Jr CVP,Strategy/Corp Development
- Chopra Daveen CVP, TMTT & Surgical
- Lippis Daniel J. CVP, TAVR
- Markowitz Wayne CVP, JAPAC
Officers and board are drawn from EW’s recent SEC ownership filings (Forms 3, 4 and 5).
Notable recent eventspast year
- May 8 Officer or director change reported in an 8-K
- May 4 Officer or director change reported in an 8-K
- Apr 24 +5.6% one-day move
- Dec 31, 2025 FY2025 net income −74% YoY
- Oct 30, 2025 Officer or director change reported in an 8-K
- Oct 27, 2025 +6.2% one-day move
- Jul 25, 2025 Officer or director change reported in an 8-K
- Jul 25, 2025 +5.5% one-day move
Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.
Recent SEC filingssynced from SEC 51d ago
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- DEF 14A Proxy statement
- 10-K Annual report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report